Vaccination status and disease severity of COVID-19 in different phases of the pandemic

References

• Faria NR, Claro, IM, Candido D, Franco, LM, Andrade, PS, Coletti, TM, Silva, CA, Sales, FC, Manuli, ER, Aguiar, R, et al. Genomic characterisation of an emergent SARS-CoV-2 lineage in Manaus: preliminary findings. Virological. 2021;372:815–9.
   Google Scholar
• European Centre for Disease Prevention and Control. SARS-CoV-2 variants of concern as of 26 August 2021. 2021 [accessed 2022 Jul 5]. https://www.ecdc.europa.eu/en/covid-19/variants-concern.
   Google Scholar
• Bhattacharya S, Basu P, Poddar S. Changing epidemiology of SARS-CoV in the context of COVID-19 pandemic. J Prev Med Hyg. 2020;61(2):E130. doi:10.2139/ssrn.3722801.
   PubMedGoogle Scholar
• Vimercati L, Stefanizzi P, De Maria L, Caputi A, Cavone D, Quarato M, Gesualdo L, Lopalco PL, Migliore G, Sponselli S. et al. Large-scale IgM and IgG SARS-CoV-2 serological screening among healthcare workers with a low infection prevalence based on nasopharyngeal swab tests in an Italian university hospital: Perspectives for public health. Environ Res. 2021;195:110793. doi:10.1016/j.envres.2021.110793.
   PubMed Web of Science ®Google Scholar
• Patone M, Thomas K, Hatch R, Tan PS, Coupland C, Liao W, Mouncey P, Harrison D, Rowan K, Horby P. et al. Mortality and critical care unit admission associated with the SARS-CoV-2 lineage B.1.1.7 in England: an observational cohort study. Lancet Infect Dis. 2021;21(11):1518–28. doi:10.1016/S1473-3099(21)00318-2.
   PubMed Web of Science ®Google Scholar
• Lin L, Liu Y, Tang X, He D. The disease severity and clinical outcomes of the SARS-CoV-2 variants of concern. Front Public Health. 2021;9:775224. doi:10.3389/fpubh.2021.775224.
   PubMed Web of Science ®Google Scholar
• Walensky RP, Walke HT, Fauci AS. SARS-CoV-2 variants of concern in the United States-challenges and opportunities. JAMA. 2021;325(11):1037–8. doi:10.1001/jama.2021.2294.
   PubMed Web of Science ®Google Scholar
• Griffin JB, Haddix M, Danza P, Fisher R, Koo TH, Traub E, Gounder P, Jarashow C, Balter S. SARS-CoV-2 infections and hospitalizations among persons aged ≥16 years, by vaccination status — Los Angeles County, California, May 1–July 25, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(34):1170–6. doi:10.15585/mmwr.mm7034e5.
   PubMed Web of Science ®Google Scholar
• Herlihy R, Bamberg W, Burakoff A, Alden N, Severson R, Bush E, Kawasaki B, Berger B, Austin E, Shea M. et al. Rapid Increase in Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant – Mesa County, Colorado, April–June 2021. MMWR Morb Mortal Wkly Rep. 2021;70(32):1084–7. doi:10.15585/mmwr.mm7032e2.
   PubMed Web of Science ®Google Scholar
• South Carolina Department of Health and Environmental Control. COVID-19 Variant Dashboard. 2022 [accessed 2022 June 6]. https://scdhec.gov/covid19/covid-19-variants.
   Google Scholar
• Davies NG, Jarvis CI, Edmunds WJ, Jewell NP, Diaz-Ordaz K, Keogh RH. Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7. Nature. 2021;593(7858):270–4. doi:10.1038/s41586-021-03426-1.
   PubMed Web of Science ®Google Scholar
• Challen R, Brooks-Pollock E, Read JM, Dyson L, Tsaneva-Atanasova K, Danon L. Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study. BMJ. 2021;372:n579. doi:10.1136/bmj.n579.
   PubMed Web of Science ®Google Scholar
• Frampton D, Rampling T, Cross A, Bailey H, Heaney J, Byott M, Scott R, Sconza R, Price J, Margaritis M. et al. Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage in London, UK: a whole-genome sequencing and hospital-based cohort study. Lancet Infect Dis. 2021;21(9):1246–56. doi:10.1016/S1473-3099(21)00170-5.
   PubMed Web of Science ®Google Scholar
• Liu Y, Rocklov J. The reproductive number of the Delta variant of SARS-CoV-2 is far higher compared to the ancestral SARS-CoV-2 virus. J Travel Med. 2021;28(7). doi:10.1093/jtm/taab124.
   Web of Science ®Google Scholar
• Augusto G, Mohsen MO, Zinkhan S, Liu X, Vogel M, Bachmann MF. In vitro data suggest that Indian delta variant B.1.617 of SARS-CoV-2 escapes neutralization by both receptor affinity and immune evasion. Allergy. 2022;77(1):111–17. doi:10.1111/all.15065.
   PubMed Web of Science ®Google Scholar
• Teyssou E, Delagrèverie H, Visseaux B, Lambert-Niclot S, Brichler S, Ferre V, Marot S, Jary A, Todesco E, Schnuriger A. et al. The Delta SARS-CoV-2 variant has a higher viral load than the Beta and the historical variants in nasopharyngeal samples from newly diagnosed COVID-19 patients. J Infect. 2021;83(4):1–3. doi:10.1016/j.jinf.2021.08.027.
   PubMed Web of Science ®Google Scholar
• Twohig KA, Nyberg T, Zaidi A, Thelwall S, Sinnathamby MA, Aliabadi S, Seaman SR, Harris RJ, Hope R, Lopez-Bernal J. et al. Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study. Lancet Infect Dis. 2022;22(1):35–42. doi:10.1016/S1473-3099(21)00475-8.
   PubMed Web of Science ®Google Scholar
• Ong SWX, Chiew CJ, Ang LW, Mak T-M, Cui L, Toh MPH, Lim YD, Lee PH, Lee TH, Chia PY. et al. Clinical and virological features of SARS-CoV-2 variants of concern: a retrospective cohort study comparing B.1.1.7 (Alpha), B.1.315 (Beta), and B.1.617.2 (Delta). Clin Infect Dis. 2021; doi:10.2139/ssrn.3861566.
   Web of Science ®Google Scholar
• HHS.gov. COVID-19 vaccines. 2022 [accessed 2022 Aug 4]. https://www.hhs.gov/coronavirus/covid-19-vaccines/index.html.
   Google Scholar
• Moscara L, Venerito V, Martinelli A, Di Lorenzo A, Toro F, Violante F, Tafuri S, Stefanizzi P. Safety profile and SARS-CoV-2 breakthrough infections among HCWs receiving anti-SARS-CoV-2 and influenza vaccines simultaneously: an Italian observational study. Vaccine. 2023;41(38):5655–61. doi:10.1016/j.vaccine.2023.07.043.
   PubMed Web of Science ®Google Scholar
• Nanduri S, Pilishvili T, Derado G, Soe MM, Dollard P, Wu H, Li Q, Bagchi S, Dubendris H, Link-Gelles R. et al. Effectiveness of Pfizer-BioNTech and moderna vaccines in preventing SARS-CoV-2 infection among nursing home residents before and during widespread circulation of the SARS-CoV-2 B.1.617.2 (Delta) variant - national healthcare safety network, March 1-August 1, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(34):1163–6. doi:10.15585/mmwr.mm7034e3.
   PubMed Web of Science ®Google Scholar
• Bernal JL, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, Stowe J, Tessier E, Groves N, Dabrera G, et al. Effectiveness of COVID-19 vaccines against the B. 1.617. 2 (Delta) variant. N Engl J Med. 2021;386:585–594.
   Web of Science ®Google Scholar
• Tang P, Hasan MR, Chemaitelly H, Yassine HM, Benslimane FM, Al Khatib HA, AlMukdad S, Coyle P, Ayoub HH, Al Kanaani Z. et al. BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar. Nat Med. 2021;27(12):2136–43. doi:10.1038/s41591-021-01583-4.
   PubMed Web of Science ®Google Scholar
• Puranik A, Lenehan, PJ, Silvert E, Niesen, MJ, Corchado-Garcia J, O’Horo, JC, Virk A, Swift, MD, Halamka J, Badley, AD, et al. Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence. Med. 2022;3:28–41.e8.
   PubMedGoogle Scholar
• De Maria L, Sponselli S, Caputi A, Pipoli A, Giannelli G, Delvecchio G, Zagaria S, Cavone D, Stefanizzi P, Bianchi FP. et al. Comparison of three different waves in healthcare workers during the COVID-19 pandemic: a retrospective observational study in an Italian University Hospital. J Clin Med. 2022;11(11):3074. doi:10.3390/jcm11113074.
   PubMed Web of Science ®Google Scholar
• Yang B, Lin Y, Xiong W, Liu C, Gao H, Ho F, Zhou J, Zhang R, Wong JY, Cheung JK. et al. Comparison of control and transmission of COVID-19 across epidemic waves in Hong Kong: an observational study. Lancet Reg Health–West Pac. 2024;43:43. doi:10.1016/j.lanwpc.2023.100969.
   Google Scholar
• Council of State and Territorial Epidemiologists. Standardized surveillance case definition and national notification for 2019 Novel Coronavirus Disease (COVID-19). 2020. https://cdn.ymaws.com/www.cste.org/resource/resmgr/2020ps/Interim-20-ID-01_COVID-19.pdf.
   Google Scholar
• SCDHEC. South Carolina List of Reportable Conditions. 2021. https://scdhec.gov/health-professionals/south-carolina-list-reportable-conditions.
   Google Scholar
• SC Department of Health and Environmental Control. COVID-19 Compendium of Reporting. 2021 [accessed 2022 Nov 2]. https://scdhec.gov/sites/default/files/Library/CR-012859.pdf.
   Google Scholar
• Policy OORH. List of rural counties and designated eligible census tracts in metropolitan counties. 2010. https://www.hrsa.gov/sites/default/files/hrsa/ruralhealth/resources/forhpeligibleareas.pdf.
   Google Scholar
• Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, Januel J-M, Sundararajan V. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676–82. doi:10.1093/aje/kwq433.
   PubMed Web of Science ®Google Scholar
• Tenforde MW, Self WH, Adams K, Gaglani M, Ginde AA, McNeal T, Ghamande S, Douin DJ, Talbot HK, Casey JD. et al. Association between mRNA vaccination and COVID-19 hospitalization and disease severity. JAMA. 2021;326(20):2043–54. doi:10.1001/jama.2021.19499.
   PubMed Web of Science ®Google Scholar
• Sun J, Zheng Q, Madhira V, Olex AL, Anzalone AJ, Vinson A, Singh JA, French E, Abraham AG, Mathew J. et al. Association between immune dysfunction and COVID-19 breakthrough infection after SARS-CoV-2 vaccination in the US. JAMA internal medicine. JAMA Internal Medicine. 2022;182(2):153–62. doi:10.1001/jamainternmed.2021.7024.
   PubMed Web of Science ®Google Scholar
• Vinceti M, Filippini T, Rothman KJ, Di Federico S, Orsini N. The association between first and second wave COVID-19 mortality in Italy. BMC Public Health. 2021;21(1):1–9. doi:10.1186/s12889-021-12126-4.
   PubMed Web of Science ®Google Scholar
• Hall V, Foulkes S, Insalata F, Kirwan P, Saei A, Atti A, Wellington E, Khawam J, Munro K, Cole M. et al. Protection against SARS-CoV-2 after Covid-19 vaccination and previous infection. N Engl J Med. 2022;386(13):1207–20. doi:10.1056/NEJMoa2118691.
   PubMed Web of Science ®Google Scholar
• Tenforde MW, Link-Gelles R, Patel MM. Long-term protection associated with COVID-19 vaccination and prior infection. JAMA. 2022;328(14):1402–4. doi:10.1001/jama.2022.14660.
   PubMed Web of Science ®Google Scholar
• Collatuzzo G, Visci G, Violante FS, Porru S, Spiteri G, Monaco MGL, Larese Fillon F, Negro C, Janke C, Castelletti N. et al. Determinants of anti-S immune response at 6 months after COVID-19 vaccination in a multicentric European cohort of healthcare workers–ORCHESTRA project. Front Immunol. 2022;13:986085. doi:10.3389/fimmu.2022.986085.
   PubMed Web of Science ®Google Scholar
• Chico-Sánchez P, Gras-Valentí P, Algado-Sellés N, Jiménez-Sepúlveda N, Vanaclocha H, Peiró S, Burgos JS, Berenguer A, Navarro D, Sánchez-Payá J. et al. The effectiveness of mRNA vaccines to prevent SARS-CoV-2 infection and hospitalisation for COVID-19 according to the time elapsed since their administration in health professionals in the Valencian Autonomous Community (Spain). Prev Med. 2022;163:107237. doi:10.1016/j.ypmed.2022.107237.
   PubMed Web of Science ®Google Scholar
• Zheng C, Shao W, Chen X, Zhang B, Wang G, Zhang W. Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis. Int J Infect Dis. 2022;114:252–60. doi:10.1016/j.ijid.2021.11.009.
   PubMed Web of Science ®Google Scholar
• Juthani PV, Gupta A, Borges KA, Price CC, Lee AI, Won CH, Chun HJ. Hospitalisation among vaccine breakthrough COVID-19 infections. Lancet Infect Dis. 2021;21(11):1485–6. doi:10.1016/S1473-3099(21)00558-2.
   PubMed Web of Science ®Google Scholar
• Fitz-Patrick D, Young M, Yacisin K, McElwee K, Belanger T, Belanger K, Peng Y, Lee D-Y, Gruber WC, Scott DA. et al. Randomized trial to evaluate the safety, tolerability, and immunogenicity of a booster (third dose) of BNT162b2 COVID-19 vaccine coadministered with 20-valent pneumococcal conjugate vaccine in adults≥ 65 years old. Vaccine. 2023;41(28):4190–8. doi:10.1016/j.vaccine.2023.05.002.
   PubMed Web of Science ®Google Scholar
• Janssen C, Mosnier A, Gavazzi G, Combadière B, Crépey P, Gaillat J, Launay O, Botelho-Nevers E. Coadministration of seasonal influenza and COVID-19 vaccines: A systematic review of clinical studies. Hum Vaccines Immunother. 2022;18(6):2131166. doi:10.1080/21645515.2022.2131166.
   PubMed Web of Science ®Google Scholar
• Anzalone AJ, Horswell R, Hendricks BM, Chu S, Hillegass WB, Beasley WH, Harper JR, Kimble W, Rosen CJ, Miele L. et al. Higher hospitalization and mortality rates among SARS‐CoV‐2‐infected persons in rural America. J Rural Health. 2023;39(1):39–54. doi:10.1111/jrh.12689.
   PubMed Web of Science ®Google Scholar